ANAPTYSBIO, INC. (ANAB) Return on equity 2018–2026
ANAPTYSBIO, INC. (ANAB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-35.6%FY2026 · since FY2018: -9.8% → -35.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -35.6% | +169.4 pp |
| FY2025 | -204.9% | -19.2 pp |
| FY2024 | -185.7% | -136.6 pp |
| FY2023 | -49.1% | -32.9 pp |
| FY2022 | -16.2% | -11.2 pp |
| FY2021 | -5.0% | +19.0 pp |
| FY2020 | -24.0% | -11.4 pp |
| FY2019 | -12.7% | -2.9 pp |
| FY2018 | -9.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ANAB financial trends
ANAB RevenueANAB Net incomeANAB Net marginANAB Gross profitANAB Gross marginANAB Operating incomeANAB Operating marginANAB Operating cash flowANAB Free cash flowANAB Capital expendituresANAB Stock buybacksANAB Dividends paidANAB Total assetsANAB Total liabilitiesANAB Shareholders’ equityANAB overview →